Second malignant neoplasms are a serious complication after successful treatment of childhood acute lymphoblastic leukemia (ALL). With improvement in survival, it is important to assess the impact of contemporary risk-based therapies on second neoplasms in ALL survivors. A cohort of 8831 children diagnosed with ALL and enrolled on Children's Cancer Group therapeutic protocols between 1983 and 1995 were observed to determine the incidence of second neoplasms and associated risk factors. The median age at diagnosis of ALL was 4.7 years. The cohort had accrued 54 883 person-years of follow-up. Sixty-three patients developed second neoplasms, including solid, nonhematopoietic tumors (n = 39: brain tumors n = 19, other solid tumors n = 20), myeloid leukemia or myelodysplasia (n = 16), and lymphoma (n = 8). The cumulative incidence of any second neoplasm was 1.18% at 10 years (95% confidence interval, 0.8%-1.5%), representing a 7.2-fold increased risk compared with the general population. The risk was increased significantly for acute myeloid leukemia (standardized incidence ratio [SIR] 52.3), non-Hodgkin lymphoma (SIR 8.3), parotid gland tumors (SIR 33.4), thyroid cancer (SIR 13.3), brain tumors (SIR 10.1), and soft tissue sarcoma (SIR 9.1). Multivariate analysis revealed female sex (relative risk [RR] 1.8), radiation to the craniospinal axis (RR 1.6), and relapse of primary disease (RR 3.5) to be independently associated with increased risk of all second neoplasms. Risk of second neoplasms increased with radiation dose (1800 cGy RR 1.5; 2400 cGy RR 3.9). Actuarial survival at 10 years from diagnosis of second neoplasms was 39%. Follow-up of this large cohort that was treated with contemporary risk-based therapy showed that the incidence of second neoplasms remains low after diagnosis of childhood ALL.

Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with an annual rate of 3 to 4 cases per 100 000 children.1 Population-based data indicate that children with ALL treated with contemporary therapy have a 5-year survival rate of 80%.2 With 2500 to 3000 children diagnosed with ALL annually, we expect approximately 2000 long-term survivors of childhood ALL each year. Long-term sequelae of treatment, such as impaired intellectual and psychomotor functioning,3 neuroendocrine abnormalities,4impaired reproductive capacity,5-8cardiotoxicity,9 and second malignant neoplasms10-17 are being reported with increased frequency in the growing cohort of survivors.

For survivors of childhood ALL, the estimated actuarial risk of developing a second neoplasm has been reported to be 2.5% at 15 years from diagnosis.11 Among second neoplasms observed after treatment of ALL, central nervous system (CNS) tumors in patients treated with cranial irradiation are the most common. Other commonly reported second neoplasms in this population include lymphoma, acute myeloid leukemia (AML), and thyroid cancer.10,11,13,14,18-31 However, most reports of second neoplasms are limited by relatively few patients treated on contemporary risk-based therapeutic protocols and observed for reasonable lengths of time. To address these concerns, we followed a cohort of 8831 children who had been treated on 1 of the 12 Children's Cancer Group (CCG) therapeutic protocols between 1983 and 1995 and had accrued 54 883 person-years of follow-up. Among 8831 patients, 3599 (41%) had been part of a previous report.11 The follow-up of these 3599 patients was 6 years (range, 3 to 8 years) at the time of that report.11 Therefore, this study is an update of the previous report (increased follow-up to a median of 15 years) and an extension of the cohort to include 5232 additional patients.

The CCG conducted clinical trials in cooperation with member institutions throughout the United States and Canada. At the time of analysis, the group included 122 institutions, which were required to register all newly diagnosed cancer patients with the operations office, after which eligible patients were entered into active therapeutic clinical trials. The operations office was responsible for determining patient eligibility, randomized assignments to the appropriate therapeutic arms (if necessary), and follow-up of patients for all potential outcomes. Member institutions were required to submit follow-up reports on all patients enrolled in therapeutic protocols. Those reports included information on survival status, disease status, and development of second malignancies for all patients. The follow-up reports are submitted annually for as long as patients live.

Our cohort consisted of 8831 children with newly diagnosed ALL who were younger than 21 years at diagnosis and were enrolled in 1 of the 12 therapeutic protocols for untreated ALL conducted by CCG between 1983 and 1995. These twelve protocols were CCG-104, -105, -106, -107, -123, -139, -1881, -1882, -1883, -1891, -1901, and -1922. Informed consent was obtained from patients, parents, or guardians at the time of enrollment. The patients were randomized to 1 of 2 or more therapeutic schedules of chemotherapy or radiation. The total length of therapy ranged from 2 to 3 years. Clinical results of many of the trials, with the therapeutic plans, have been published.32-42 

For each protocol, a therapeutic summary was prepared that included the dose of radiation therapy (and assigned fields) and chemotherapeutic exposures. Assigned cumulative doses were calculated for cyclophosphamide and the anthracyclines (daunomycin and doxorubicin). The total assigned cumulative doses ranged from 0 to 16 200 (females) and 24 000 (males) mg/m2 of body surface area for cyclophosphamide and from 0 to 500 mg/m2 of body surface area for anthracyclines. Assigned radiation doses ranged from 0 to 1800 cGy to the cranium (for CNS prophylaxis) and 2400 cGy to the cranium and 600 to 1200 cGy to the spine (for treatment of CNS disease). The authors reviewed the records of patients with second neoplasms to assess the actual doses of chemotherapeutic agents given to them. Most patients received more than 95% of their prescribed doses of parenteral chemotherapeutic agents. The actual doses given to the patients of oral drugs such as methotrexate and 6-MP were lower (73%), but exposure to oral antimetabolites was not evaluated in our analyses.

Patients also were categorized into “early” and “recent” treatment eras. The early treatment era corresponded to the period when patients were treated according to 1 of 6 therapeutic protocols open between 1983 and 1989 (CCG-104, -105, -106, -107, -123, and -139 [n = 3713]). The recent treatment era corresponded to the period when patients were treated according to the remaining 6 therapeutic protocols open between 1989 and 1995 (CCG-1881, -1882, -1883, -1891, -1901, and -1922 [n = 5118]).

For patients in whom second neoplasms developed, date of diagnosis, histologic characteristics, and tumor site were recorded. Pathology reports were obtained from treating institutions and reviewed to verify diagnoses.

The time at risk for second neoplasms was computed from the date of diagnosis of ALL to the date of diagnosis of second neoplasm, date of death, or date of last contact, whichever came first. The end of follow-up for the study was December 1999. Overall and event-free survival was calculated using actuarial methods. Cumulative incidence of second malignancy over time was calculated using competing risk methods. To estimate the risk of second neoplasms, the number of person-years of observation were compiled for subgroups of the cohort, defined by age and sex. Rates of incidence of cancer (obtained from the registry of Surveillance, Epidemiology, and End Results Program of the National Institutes of Health2) were used to calculate the expected number of cases of cancer. Standardized incidence ratios (SIRs) were calculated as the ratios of observed to expected cases. Cox regression techniques were used for calculating relative risk (RR) estimates.43 Variables examined in the regression model included age at diagnosis, sex, cumulative cyclophosphamide and anthracycline doses, and radiation dose delivered to the craniospinal axis. Age at diagnosis of ALL was analyzed as a categorical variable (less than or equal to 5 years vs more than 5 years). Exposures to cyclophosphamide and anthracyclines also were analyzed as categorical variables (cyclophosphamide dose 0 mg/m2, 1-2000 mg/m2, and more than 2000 mg/m2; anthracyclines 0 mg/m2, 1-200 mg/m2, and more than 200 mg/m2). Epipodophyllotoxins were not used in any of the CCG therapeutic protocols. Although all patients in our cohort were treated according to therapeutic protocols, we did not have information regarding the treatment received by patients in the event of relapse, which potentially could have influenced development of second malignancies. Therefore, we included relapse of primary disease as a variable in the multivariate analysis. All tests of statistical significance were 2-sided.

Excess absolute risk was calculated as an additional indicator of impact of cancer diagnosis and therapy on the cohort when compared with the general population. Excess absolute risk was determined by subtracting the expected number of malignancies in the cohort from the observed number, dividing the difference by person-years of follow-up, and multiplying that value by 10 000.

The cohort was observed for a median of 5.5 years (range, 0 to 16.1 years). During the study, there was documented contact with 90% of patients within the previous 5 years and 78% within the previous 2 years. The estimated overall survival at 9 years was 76.9% ± 0.5%, and the event-free survival was 67.2% ± 0.6%. Sixty-three patients developed second neoplasms, including 39 patients with solid, nonhematopoietic tumors, 16 with acute and chronic myeloid leukemia or myelodysplasia (MDS), 6 with non-Hodgkin lymphoma (NHL), and 2 with Hodgkin disease. Characteristics of the patient population and treatment received are summarized in Table 1. The median length of follow-up among the patients who survive second cancers is 3 years (range, 0 to 12 years).

Table 1.

Characteristics of the patient population

CharacteristicsPatients with second cancer
Total
cohort
Brain
tumor
AML/MDS*HDNHLSarcomaThyroid
cancer
Parotid tumorsOther solid tumors
No. of patients 8831 19 14 
Male sex, % of cohort 57% 37% 71% 50% 67% 0% 50% 50% 50% 
Age at diagnosis of ALL          
 Median, y 4.7 3.8 4.8 9.0 5.6 8.0 2.9 2.9 11.8 
 Range, y 0-20.8 1.3-15.5 1.6-15.8 3.8-14.3 1.3-8.1  1.9-14.1 1.5-4.0  1.8-14.9 0.2-17.4 
 5 y or less, % of cohort 54% 68% 57% 50% 50% 50% 100% 75% 13% 
Time to 2nd neoplasms, y          
 Median — 7.1 3.1 2.3 3.1 3.6 9.7 8.9  7.9 
 Range — 3.9-13.0 0.9-10.7 1.9-2.6  1.5-12.7 2.4-5.6  5.5-11.8 5.2-15.8 1.1-15.7 
Treatment, % of cohort          
 Cyclophosphamide 79% 68% 85% 100% 67% 100% 100% 75% 86% 
 Anthracyclines 79% 68% 85% 100% 67% 100% 100% 75% 86% 
 Radiation 38% 63% 50% 50% 17% 50% 50% 75% 63% 
CharacteristicsPatients with second cancer
Total
cohort
Brain
tumor
AML/MDS*HDNHLSarcomaThyroid
cancer
Parotid tumorsOther solid tumors
No. of patients 8831 19 14 
Male sex, % of cohort 57% 37% 71% 50% 67% 0% 50% 50% 50% 
Age at diagnosis of ALL          
 Median, y 4.7 3.8 4.8 9.0 5.6 8.0 2.9 2.9 11.8 
 Range, y 0-20.8 1.3-15.5 1.6-15.8 3.8-14.3 1.3-8.1  1.9-14.1 1.5-4.0  1.8-14.9 0.2-17.4 
 5 y or less, % of cohort 54% 68% 57% 50% 50% 50% 100% 75% 13% 
Time to 2nd neoplasms, y          
 Median — 7.1 3.1 2.3 3.1 3.6 9.7 8.9  7.9 
 Range — 3.9-13.0 0.9-10.7 1.9-2.6  1.5-12.7 2.4-5.6  5.5-11.8 5.2-15.8 1.1-15.7 
Treatment, % of cohort          
 Cyclophosphamide 79% 68% 85% 100% 67% 100% 100% 75% 86% 
 Anthracyclines 79% 68% 85% 100% 67% 100% 100% 75% 86% 
 Radiation 38% 63% 50% 50% 17% 50% 50% 75% 63% 

HD indicates Hodgkin disease.

*

Does not include the patients with chronic myelogenous leukemia (n = 1) and chronic myelomonocytic leukemia (n = 1).

Figure 1 shows the cumulative incidence of all second neoplasms, AMLs, all solid cancers, and brain tumors. The cumulative incidence of any second malignant neoplasm was 1.18% (95% confidence interval [CI], 0.8%-1.5%) at 10 years from diagnosis of ALL and rose to 2.08% (95% CI, 1.4%-2.8%) at 15 years. Most of this risk was from solid nonhematopoietic malignancies including brain tumors (cumulative incidence 0.82% at 10 years). Among patients who remained in first continued remission, the cumulative incidence of any second malignancy was 0.91% (95% CI, 0.6%-1.2%) at 10 years from diagnosis. The cumulative incidence by type of second malignancy for the entire cohort and for those in first continued remission is shown in Table 2.

Fig. 1.

Cumulative incidence of all second neoplasms, AML/MDS, all solid tumors, and brain tumors in 8831 children with ALL.

Fig. 1.

Cumulative incidence of all second neoplasms, AML/MDS, all solid tumors, and brain tumors in 8831 children with ALL.

Close modal
Table 2.

Cumulative incidence of second neoplasms among patients treated for childhood ALL

Type/site of
second malignancies
Cumulative incidence (95% CI)
Entire cohortPatients remaining in
initial remission of ALL
All second malignancies 10 y: 1.18% (0.8%-1.5%) 10 y: 0.91% (0.6%-1.2%) 
 15 y: 2.08% (1.4%-2.8%) 15 y: 1.48% (0.9%-2.1%) 
All solid malignancies 10 y: 0.82% (0.5%-1.1%) 10 y: 0.63% (0.3%-0.9%)  
 15 y: 1.55% (0.9%-2.2%) 15 y: 1.0% (0.5%-1.5%)  
Brain tumors 10 y: 0.47% (0.2%-0.6%) 10 y: 0.40% (0.2%-0.6%)  
 15 y: 0.90% (0.4%-1.4%) 15 y: 0.61% (0.2%-1.0%)  
AML/MDS 10 y: 0.21% (0.1%-0.3%) 10 y: 0.14% (0.03%-0.2%)  
 15 y: 0.27% (0.1%-0.4%) 15 y: 0.21% (0.03%-0.4%)  
NHL 10 y: 0.08% (0.01%-0.2%) 10 y: 0.05% (0%-0.1%)  
 15 y: 0.19% (0.01%-0.4%) 15 y: 0.18% (0%-0.5%) 
Type/site of
second malignancies
Cumulative incidence (95% CI)
Entire cohortPatients remaining in
initial remission of ALL
All second malignancies 10 y: 1.18% (0.8%-1.5%) 10 y: 0.91% (0.6%-1.2%) 
 15 y: 2.08% (1.4%-2.8%) 15 y: 1.48% (0.9%-2.1%) 
All solid malignancies 10 y: 0.82% (0.5%-1.1%) 10 y: 0.63% (0.3%-0.9%)  
 15 y: 1.55% (0.9%-2.2%) 15 y: 1.0% (0.5%-1.5%)  
Brain tumors 10 y: 0.47% (0.2%-0.6%) 10 y: 0.40% (0.2%-0.6%)  
 15 y: 0.90% (0.4%-1.4%) 15 y: 0.61% (0.2%-1.0%)  
AML/MDS 10 y: 0.21% (0.1%-0.3%) 10 y: 0.14% (0.03%-0.2%)  
 15 y: 0.27% (0.1%-0.4%) 15 y: 0.21% (0.03%-0.4%)  
NHL 10 y: 0.08% (0.01%-0.2%) 10 y: 0.05% (0%-0.1%)  
 15 y: 0.19% (0.01%-0.4%) 15 y: 0.18% (0%-0.5%) 

At the time of analysis, the cohort had accrued 54 883 person-years of follow-up. The number of observed and expected second neoplasms, calculated on the basis of age- and sex-specific rates for all cancers and various groupings of cancers, are shown in Table3. Overall, a total of 8.5 neoplasms would have been expected, and 61 (excluding the 2 patients with meningioma) were observed (SIR 7.2; 95% CI, 5.5-9.1). In addition, significantly elevated risks were observed for AML or MDS (AML/MDS) (SIR 52.3), NHL (SIR 8.3), brain tumors (SIR 10.1), soft tissue sarcoma (SIR 9.1), thyroid cancer (SIR 13.3), and parotid gland tumors (SIR = 33.4). The absolute risk for all cancers was 9.6 cases per 10 000 patients per year and ranged from 0.2 cases per 10 000 patients per year for Hodgkin disease to 2.8 cases for brain tumors (Table 3).

Table 3.

Observed and expected rates of second neoplasms, according to type or site

Type or siteObserved/expected casesSIR (95% CI)Absolute risk per 104 y
All cancers3-150 61/8.5 7.2  (5.5-9.1) 9.6  
Leukemia 16/0.3 59.4  (33.9-96.4) 2.9 
 AML/MDS3-151 14/0.3 52.3  (28.6-87.7) 2.5 
Lymphoma    
 NHL3-152 5/0.6 8.3  (2.6-17.2) 0.8  
 Hodgkin disease 2/0.7 2.7  (0.3-9.7) 0.2  
Solid cancers3-153    
 Brain tumors 17/1.7 10.1  (5.9-16.2) 2.8  
 Soft tissue sarcoma 4/0.4 9.1  (2.4-20.2) 0.7  
 Thyroid cancer 4/0.3 13.3  (3.6-34.1) 0.7  
 Parotid gland tumors 4/0.1 33.4  (9.1-85.6) 0.7 
Type or siteObserved/expected casesSIR (95% CI)Absolute risk per 104 y
All cancers3-150 61/8.5 7.2  (5.5-9.1) 9.6  
Leukemia 16/0.3 59.4  (33.9-96.4) 2.9 
 AML/MDS3-151 14/0.3 52.3  (28.6-87.7) 2.5 
Lymphoma    
 NHL3-152 5/0.6 8.3  (2.6-17.2) 0.8  
 Hodgkin disease 2/0.7 2.7  (0.3-9.7) 0.2  
Solid cancers3-153    
 Brain tumors 17/1.7 10.1  (5.9-16.2) 2.8  
 Soft tissue sarcoma 4/0.4 9.1  (2.4-20.2) 0.7  
 Thyroid cancer 4/0.3 13.3  (3.6-34.1) 0.7  
 Parotid gland tumors 4/0.1 33.4  (9.1-85.6) 0.7 
F3-150

Excludes 2 patients with meningioma.

F3-151

Excludes the 2 patients with chronic leukemia.

F3-152

Excludes 1 patient with Epstein-Barr virus–associated B-cell lymphoproliferative disease.

F3-153

Excludes lymphatic and hematopoietic tumors. The sum of the solid tumors does not equal the total number given because only types for which the risk was significantly elevated were included.

We also estimated the SIR of second neoplasms according to period of observation (ie, the interval from first treatment to diagnosis of second neoplasm) (Table 4). The SIR was highest during the first 10 years of follow-up and declined thereafter. This phenomenon is consistent with the increase in the expected incidence of cancer with increasing age. For leukemia, the excess risk appeared within the first 5 years of treatment and declined over the next 5 years. No cases of leukemia were observed beyond 10 years after diagnosis of ALL.

Table 4.

SIRs for second neoplasms, according to length of follow-up

Type of cancerLength of follow-up
0-5 y6-10 y11-15 yMore than 15 y
No. of patients  3 905  3 007  1 761   156 
Person-years of observation 11 218 19 953 21 340 2 371 
All second cancers4-150     
 Observed  35  18 
 Observed:expected (95% CI) 20.6 (5.8-28) 6.1 (3.6-9.3) 2.3 (1.0-4.3) —  
Solid tumors4-150,4-151     
 Observed  14  16 
 Observed:expected (95% CI) 12.7 (6.9-20.3) 8.9 (5.1-13.8) 3.3 (1.3-6.3) — 
Leukemia     
 Observed  13 
 Observed:expected (95% CI) 233.9 (137.9-350.5) 31.6 (5.9-77.4) — — 
Lymphoma     
 Observed 
 Observed:expected (95% CI) 20.0 (5.2-44.4) — — — 
CNS tumors4-150     
 Observed  11 
 Observed:expected (95% CI) 10.8 (2.8-24) 17.5 (8.7-29.3) 3.2 (0.3-9.1) — 
Type of cancerLength of follow-up
0-5 y6-10 y11-15 yMore than 15 y
No. of patients  3 905  3 007  1 761   156 
Person-years of observation 11 218 19 953 21 340 2 371 
All second cancers4-150     
 Observed  35  18 
 Observed:expected (95% CI) 20.6 (5.8-28) 6.1 (3.6-9.3) 2.3 (1.0-4.3) —  
Solid tumors4-150,4-151     
 Observed  14  16 
 Observed:expected (95% CI) 12.7 (6.9-20.3) 8.9 (5.1-13.8) 3.3 (1.3-6.3) — 
Leukemia     
 Observed  13 
 Observed:expected (95% CI) 233.9 (137.9-350.5) 31.6 (5.9-77.4) — — 
Lymphoma     
 Observed 
 Observed:expected (95% CI) 20.0 (5.2-44.4) — — — 
CNS tumors4-150     
 Observed  11 
 Observed:expected (95% CI) 10.8 (2.8-24) 17.5 (8.7-29.3) 3.2 (0.3-9.1) — 
F4-150

Excludes 2 patients with meningioma.

F4-151

Excludes lymphatic and hematopoietic tumors.

Twenty-one of 63 second malignancies developed among patients who had relapses of their original diseases before diagnosis of second malignancy. The records of patients who developed relapses of their original diseases before development of second neoplasms were reviewed for details of the treatment given to them. However, the records did not include details of doses and durations of therapy received for relapses; hence, it was difficult to include postrelapse therapeutic exposures in the analyses. Because detailed information on therapy after relapse of ALL was not available at the time of this analysis, presence of relapse was included as a variable in the multivariate analysis (Table 5). Multivariate analysis found female sex (RR 1.8; 95% CI, 1.1-2.8), radiation to the craniospinal axis (RR 1.6; 95% CI, 1.0-2.6), and relapse of primary disease (RR 3.5; 95% CI, 2.1-5.8) to be independently associated with increased risk of all second neoplasms. Risk of second neoplasms increased with radiation dose (1800 cGy: RR 1.5; 95% CI, 0.9-2.6; and 2400 cGy: RR 3.9; 95% CI, 1.4-11.2).

Table 5.

Risk of a second neoplasm associated with selected characteristics of patients and therapeutic exposures (multivariate analysis)

CharacteristicsRR (95% CI)
All second neoplasms
(n = 63)
Solid tumors
(n = 39)
Brain tumors
(n = 19)
AML/MDS
(n = 14)
NHL
(n = 6)
Age at diagnosis of ALL      
 0-5 y 1.0 1.0 1.0 1.0 1.0 
 More than 5 y 1.1  (0.7-1.7) 0.9  (0.5-1.7) 0.6  (0.2-1.5) 1.3  (0.5-3.7) 1.4  (0.3-6.8) 
Sex      
 Male 1.0 1.0 1.0 1.0 1.0 
 Female 1.8  (1.1-2.8)5-150 2.9  (1.5-5.8)5-150 2.5  (0.9-6.4) 0.8  (0.3-2.3) 0.6  (0.1-3.5)  
Cyclophosphamide dose      
 None 1.0 1.0 1.0 1.0 1.0 
 1-2000 mg/m2 1.2  (0.6-2.2) 1.8  (0.8-4.3) 0.7  (0.2-2.6) 5.7  (0.7-46.9) 0.8  (0.1-5.6) 
 More than 2000 mg/m2 1.4  (0.7-2.7) 1.6  (0.6-3.9) 0.9  (0.3-2.9) 5.8  (0.7-48.3) 0.9  (0.1-6.3) 
Anthracycline dose      
 None 1.0 1.0 1.0 1.0 1.0 
 1-200 mg/m2 1.2  (0.4-2.3) 1.5  (0.7-3.6) 0.6  (0.2-1.9) 5.7  (0.7-44.6) 0.6  (0.1-1.5) 
 More than 200 mg/m2 1.4  (0.6-3.3) 2.4  (0.8-6.9) 1.8  (0.5-6.5) 5.9  (0.5-65.7) Nonconvergent 
Radiation      
 No radiation given 1.0 1.0 1.0 1.0 1.0 
 Radiation given 1.6  (1.0-2.6)5-150 2.5  (1.2-5.5)5-150 2.4  (1.1-5.2)5-150 1.3  (0.5-3.8) 0.3  (0.1-2.8) 
Radiation dose      
 None 1.0 1.0 1.0 1.0 1.0 
 1800 cGy 1.5  (0.9-2.6) 2.8  (1.5-5.6)5-150 2.1  (0.7-6.3) 1.6  (0.5-4.8) 0.6  (0.2-2.3)  
 2400 cGy 3.9  (1.4-11.2)5-150 5.8  (1.3-25.3)5-150 4.2  (0.5-37.7) 4.4  (0.6-36.1) 3.6  (0.5-28.2)  
Relapse of primary disease      
 No 1.0 1.0 1.0 1.0 1.0 
 Yes 3.5  (2.1-5.8)5-150 3.1  (1.6-6.1)5-150 2.5  (0.9-7.6)5-151 3.4  (1.2-9.8)5-150 2.2  (0.4-11.8) 
CharacteristicsRR (95% CI)
All second neoplasms
(n = 63)
Solid tumors
(n = 39)
Brain tumors
(n = 19)
AML/MDS
(n = 14)
NHL
(n = 6)
Age at diagnosis of ALL      
 0-5 y 1.0 1.0 1.0 1.0 1.0 
 More than 5 y 1.1  (0.7-1.7) 0.9  (0.5-1.7) 0.6  (0.2-1.5) 1.3  (0.5-3.7) 1.4  (0.3-6.8) 
Sex      
 Male 1.0 1.0 1.0 1.0 1.0 
 Female 1.8  (1.1-2.8)5-150 2.9  (1.5-5.8)5-150 2.5  (0.9-6.4) 0.8  (0.3-2.3) 0.6  (0.1-3.5)  
Cyclophosphamide dose      
 None 1.0 1.0 1.0 1.0 1.0 
 1-2000 mg/m2 1.2  (0.6-2.2) 1.8  (0.8-4.3) 0.7  (0.2-2.6) 5.7  (0.7-46.9) 0.8  (0.1-5.6) 
 More than 2000 mg/m2 1.4  (0.7-2.7) 1.6  (0.6-3.9) 0.9  (0.3-2.9) 5.8  (0.7-48.3) 0.9  (0.1-6.3) 
Anthracycline dose      
 None 1.0 1.0 1.0 1.0 1.0 
 1-200 mg/m2 1.2  (0.4-2.3) 1.5  (0.7-3.6) 0.6  (0.2-1.9) 5.7  (0.7-44.6) 0.6  (0.1-1.5) 
 More than 200 mg/m2 1.4  (0.6-3.3) 2.4  (0.8-6.9) 1.8  (0.5-6.5) 5.9  (0.5-65.7) Nonconvergent 
Radiation      
 No radiation given 1.0 1.0 1.0 1.0 1.0 
 Radiation given 1.6  (1.0-2.6)5-150 2.5  (1.2-5.5)5-150 2.4  (1.1-5.2)5-150 1.3  (0.5-3.8) 0.3  (0.1-2.8) 
Radiation dose      
 None 1.0 1.0 1.0 1.0 1.0 
 1800 cGy 1.5  (0.9-2.6) 2.8  (1.5-5.6)5-150 2.1  (0.7-6.3) 1.6  (0.5-4.8) 0.6  (0.2-2.3)  
 2400 cGy 3.9  (1.4-11.2)5-150 5.8  (1.3-25.3)5-150 4.2  (0.5-37.7) 4.4  (0.6-36.1) 3.6  (0.5-28.2)  
Relapse of primary disease      
 No 1.0 1.0 1.0 1.0 1.0 
 Yes 3.5  (2.1-5.8)5-150 3.1  (1.6-6.1)5-150 2.5  (0.9-7.6)5-151 3.4  (1.2-9.8)5-150 2.2  (0.4-11.8) 

Risk estimates in bold identify the significant associations.

F5-150

P ≤ .05.

F5-151

.05 < P < .1.

Solid cancers

Solid nonhematopoietic cancers developed in 39 patients and included 19 with brain tumors; 4 each with thyroid cancer, parotid gland tumors, and soft tissue sarcoma; 2 each with malignant melanoma, colon cancer, and osteogenic sarcoma; and 1 each with breast and ovarian cancer. The cumulative incidence of a second solid nonhematopoietic malignancy was 0.82% (95% CI, 0.5%-1.1%) at 10 years (Figure 1; Table 2) and rose to 1.55% (95% CI, 0.9%-2.2%) at 15 years from diagnosis of ALL. The median time to development of second solid malignancies was 7.1 years (range, 1.1-15.8 years). Multivariate analysis revealed relapse of primary disease (RR 3.1; 95% CI, 1.6-6.1), female sex (RR 2.9; 95% CI, 1.5-5.8), and exposure to radiation (RR 2.5; 95% CI, 1.2-5.5) to be independently associated with an increased risk of a second solid malignancy (Table 5). The risk increased with increasing dose of radiation (1800 cGy: RR 2.8; 95% CI, 1.5-5.6; and 2400 cGy: RR 5.8; 95% CI, 1.3-25.3). Seventy-five percent of solid tumors developed within radiation fields. Seventeen of 39 patients with solid malignancies have died at the time of this report.

Brain tumors.

Brain tumors developed in 19 patients and included 9 with glioblastoma multiforme, 4 with anaplastic astrocytoma, 3 with primitive neuroectodermal tumors of the brain, 2 with meningioma, and 1 with medulloblastoma. The median age at diagnosis of ALL for these 19 patients was 3.8 years, and the median time to development of brain tumors was 7.1 years. The cumulative incidence of brain tumors approached 0.47% (95% CI, 0.2-0.6) at 10 years (Figure1), and the cohort was at a 10-fold increased risk for developing brain tumors when compared with the general population. Multivariate analysis revealed radiation to the craniospinal axis (RR 2.4; 95% CI, 1.1-5.2) to be associated with increased risk of brain tumors after ALL (Table5). Age at diagnosis of ALL was not identified as a significant risk factor. Eleven of 19 patients with brain tumors have died.

Soft tissue sarcoma.

Soft tissue sarcoma developed in 4 patients. These included rhabdomyosarcoma involving the eye, uterus (embryonal), and urinary bladder (undifferentiated) in 1 patient each and a high-grade pleomorphic sarcoma of the pelvis in the fourth patient. The patient with the uterine rhabdomyosarcoma had received total body irradiation for unrelated donor bone marrow transplantation before development of rhabdomyosarcoma. Two other patients received prophylactic radiation to the brain, but sarcomas developed outside the radiation fields. The fourth patient did not receive radiation therapy. The median time to development of secondary sarcoma was 3.6 years (range, 2.4 to 5.6 years). The cohort was at a 9.1-fold increased risk for developing soft tissue sarcoma compared with the general population. All 4 patients were females, with a significantly increased risk of developing sarcomas among the female compared with male cohort (P = .02). No other host or therapy-related risk factors were identified. Three of 4 patients with soft tissue sarcoma have died.

Parotid gland tumors.

Mucoepidermoid tumors of the parotid gland developed in 4 patients. This cohort was at a 33.4 times increased risk for developing a parotid gland tumor compared with the general population. The median time to development of those tumors was 8.9 years (range, 5.2 to 15.8 years), and no risk factors were identified. All 4 patients were alive at the time of this report.

Thyroid cancer.

Papillary carcinoma of the thyroid gland developed in 4 patients at a median of 9.7 years (range, 5.5 to 11.8 years) from diagnosis of ALL. The cohort was at a 13.3-fold increased risk for development of secondary thyroid cancers when compared with the general population. Exposure to 2400 cGy of radiation was associated with a significantly increased risk of developing thyroid cancer (RR 30.8; 95% CI, 1.2-62.9). All 4 patients with thyroid cancer were alive at the time of this report.

Leukemia

Secondary leukemia developed in 16 patients. Fourteen developed AML/MDS, 1 developed chronic myelogenous leukemia, and 1 was diagnosed with chronic myelomonocytic leukemia. Marker studies were very carefully reviewed to determine that the secondary leukemias were true second neoplasms and not relapses of original diseases. Of 14 patients with AML/MDS, 10 were characterized morphologically with AML (M0 [n = 1], M1 [n = 4], M2 [n = 2], M4 [n = 1], M5 [n = 1], M6 [n = 1]), 3 had morphologic features of MDS, and 1 developed myelofibrosis. The median time to development of AML/MDS was 3.1 years (range, 0.9-10.7 years) from diagnosis of ALL. The cumulative incidence of developing AML/MDS approached 0.21% (95% CI, 0.1-0.3) at 10 years, with 13 of 14 events reported in the first 5 years and no events reported after 10 years from diagnosis (Figure 1). Exposure to cyclophosphamide or anthracyclines was not identified as a significant risk factor for the development of AML/MDS (Table 5). However, patients with relapses of their primary diseases were at significantly higher risk for developing secondary AML/MDS (RR 3.4; 95% CI, 1.2-9.8) (Table 5). Twelve of 14 patients with secondary AML/MDS have died.

Lymphoma

NHL developed in 6 patients, including 1 with Epstein-Barr virus–associated B-cell lymphoproliferative disease. The median time to the development of NHL was 3.1 years (range, 1.5-2.7 years). The cumulative incidence of secondary NHL reached 0.08% (95% CI, 0.01-0.2) at 10 years from diagnosis of ALL (Figure 1). The cohort was at an 8-fold increased risk for developing a lymphoma when compared with the general population.

Hodgkin disease developed in 2 patients within the first 3 years of follow-up. The cohort was at a 2.7-fold increased risk for developing Hodgkin disease, but that risk was not statistically significant when compared with the general population. Both patients with Hodgkin disease were alive at the time of this report.

Treatment eras

A comparison of the patient characteristics, therapeutic exposures, treatment outcomes, and second malignancies is summarized in Table 6. Patients treated in the early treatment era were observed for a median of 10.3 years (range, 0.1 to 16.1 years). The cumulative incidence of second neoplasms among patients treated in the early era approached 0.94% (95% CI, 0.6%-1.3%) at 10 years and 1.84% (95% CI, 1.2%-2.5%) at 15 years.

Table 6.

Comparison of patient populations by treatment eras

Early eraRecent eraP
Cohort size  3 713  5 118  
Median length of follow-up, y 10.3 4.6  
 Range 0.1-16.1 0-9.1  < .001 
Person-years of follow-up 31 558 23 325  
Median age at diagnosis of ALL, y 4.6 4.7 .8 
 Range 0.0-20.7 0-20.8  
Sex, % males 59% 55% < .001  
Cyclophosphamide dose    
 None 35%  8%  
 1-2 000 mg/m2 22% 63%  
 More than 2 000 mg/m2 43% 29% < .001  
Anthracycline dose    
 None 35%  8%  
 1-200 mg/m2 47% 86%  
 More than 200 mg/m2 18%  6% < .001  
Radiation dose    
 None 49% 72%  
 1 800 cGy 49% 25%  
 2 400 cGy   2%  3% < .001 
Survival    
 Overall survival at 5 y 78.7 ± 0.7% 84.7 ± 0.5% < .001 
 Event-free survival at 5 y 65.5 ± 0.8% 74.8 ± 0.7% < .001  
Cumulative incidence of second neoplasms at 5 y (95% CI)    
 All second neoplasms 0.37% (0.2-0.5) 0.43% (0.2-0.5) .2 
 AML 0.17% (0.02-0.3) 0.15% (0.03-0.3) .4  
 NHL 0.06% (0-0.4) 0.05% (0-0.1) .2 
Early eraRecent eraP
Cohort size  3 713  5 118  
Median length of follow-up, y 10.3 4.6  
 Range 0.1-16.1 0-9.1  < .001 
Person-years of follow-up 31 558 23 325  
Median age at diagnosis of ALL, y 4.6 4.7 .8 
 Range 0.0-20.7 0-20.8  
Sex, % males 59% 55% < .001  
Cyclophosphamide dose    
 None 35%  8%  
 1-2 000 mg/m2 22% 63%  
 More than 2 000 mg/m2 43% 29% < .001  
Anthracycline dose    
 None 35%  8%  
 1-200 mg/m2 47% 86%  
 More than 200 mg/m2 18%  6% < .001  
Radiation dose    
 None 49% 72%  
 1 800 cGy 49% 25%  
 2 400 cGy   2%  3% < .001 
Survival    
 Overall survival at 5 y 78.7 ± 0.7% 84.7 ± 0.5% < .001 
 Event-free survival at 5 y 65.5 ± 0.8% 74.8 ± 0.7% < .001  
Cumulative incidence of second neoplasms at 5 y (95% CI)    
 All second neoplasms 0.37% (0.2-0.5) 0.43% (0.2-0.5) .2 
 AML 0.17% (0.02-0.3) 0.15% (0.03-0.3) .4  
 NHL 0.06% (0-0.4) 0.05% (0-0.1) .2 

Despite a significantly larger proportion of patients exposed to chemotherapeutic agents and a smaller proportion of patients exposed to prophylactic cranial irradiation in the recent era, there was no statistically significant difference in incidence of second neoplasms in the first 5 years of follow-up in the 2 treatment eras (Table 6).

Among the 8831 patients who were treated for childhood ALL since 1983 on CCG therapeutic protocols, we found the cumulative incidence of second malignancies to be low (1.18% at 10 years after the initial diagnosis). However, this report provides evidence that the risk of a second neoplasm is increased 7-fold among long-term survivors of childhood ALL when compared with the age- and sex-matched general population. The risk was highest among patients who had suffered a relapse of their primary disease, among patients who had received radiation therapy, and among females, with the sex preference primarily accounted for by secondary soft tissue sarcoma.

ALL is the most common malignancy in childhood and is associated with excellent outcomes, resulting in an increasing population of long-term survivors, so attention is being focused on potential therapy-related long-term complications such as second neoplasms.10-17,44-46 In a CCG report of 9720 patients diagnosed between 1972 and 1988 and observed for a median of 4.7 years, Neglia et al estimated a 2.5% cumulative risk of second neoplasms 15 years after diagnosis of ALL.11 Similarly, Dalton et al reported a cumulative risk of second neoplasms of 2.7% in a cohort of 1597 patients diagnosed between 1972 and 1995 who were treated according to Dana-Farber Cancer Institute protocols and observed for a median of 7.6 years.14 A population-based study of 981 children with ALL from the Nordic countries reported a cumulative risk of second neoplasms of 2.9% at 20 years from diagnosis.44Pratt et al estimated an 8% cumulative risk 15 years after diagnosis in a group of 1815 patients, diagnosed and treated on one of the St Jude protocols between 1962 to 1988, all of whom had received radiation.45 Recently, Loning et al reported a cumulative risk of 3.3% at 15 years in a cohort of 5006 patients enrolled in 5 ALL–Berlin-Frankfurt-Munster trials between 1979 and 1995 and followed for a median of 5.7 years.10 

Intrathecal chemotherapy can be effective in selected patient populations as prophylaxis against CNS leukemia47 48; therefore, radiation therapy now tends to be used primarily for children with CNS disease at diagnosis or with characteristics that indicate a high risk of CNS disease. On the other hand, chemotherapy regimens are considerably more intensive than those used in previous cohorts. Thus, our cohort of patients treated more recently and more aggressively with chemotherapy, yet more conservatively with radiation therapy, allows for assessment of incidence of second cancers in a cohort of patients who received contemporary, risk-based therapy.

Nineteen patients with brain tumors were identified in this cohort, with the cumulative incidence of brain tumors approaching 0.5% at 10 years from diagnosis of ALL. An increased risk of brain tumors has been observed among long-term survivors of childhood ALL.10,11,14,19,23-31,49 Similar to previous studies, brain tumors were more likely to develop among patients who had received radiation, and the risk increased with increasing radiation dose.10,11,14 Previous studies reported increased risk of brain tumors among patients who were less than 5 years old at the time of radiation.10,11,14,16 Thirteen of the 19 secondary brain tumors in our study developed among patients who were less than 5 years old at the time of diagnosis of ALL, but the risk of developing a secondary brain tumor did not differ statistically in the 2 age categories. An unusually high incidence of secondary brain tumors was reported among children treated on a therapeutic protocol at St Jude Children's Research Hospital.28 The St Jude protocol differed from previous protocols in that more intensive systemic antimetabolite therapy was given before and during radiotherapy. An assessment of clinical, biologic, and pharmacokinetic features revealed higher erythrocyte concentrations of thioguanine nucleotide metabolites and a higher proportion of defective thiopurine methyl transferase phenotype among patients with brain tumors compared with those without brain tumors, indicating that underlying genetic characteristics and treatment variables may contribute to the excess of brain tumors in this population.

The patients in our cohort were at a 9-fold increased risk for developing soft tissue sarcoma when compared with the general population. There was no correlation with therapeutic exposures, but the risk was significantly increased among females. Brain tumor, sarcoma, and leukemia are part of the familial Li-Fraumeni syndrome.50 Epidemiologic studies have shown that families with members who have brain tumors have increased incidence of leukemia.51 A recent report by Hisada et al shows that, compared with the general population, members of Li-Fraumeni syndrome families have an exceptionally high risk of developing multiple cancers.52 The excess risk of additional primary cancers is mainly for cancers that are characteristic of Li-Fraumeni syndrome, with the highest risk observed for survivors of childhood cancer. It is possible that there is an interaction between genetic susceptibility and radiation, resulting in a subpopulation at increased risk for developing brain tumor and soft tissue sarcoma that needs to be explored further. Unfortunately, information on family history of cancer was not available for this cohort of patients.

Case reports of parotid gland tumors as second malignancies after treatment of childhood ALL have been described,53 with patients presenting with painless swelling 6 to 7 years after treatment for ALL. Our cohort was at a 33-fold increased risk for mucoepidermoid carcinoma of the parotid gland, which developed a median of 9 years from diagnosis of ALL, and all 4 patients were alive at the time of this report.

There are several case reports of thyroid carcinoma after treatment for ALL with prophylactic cranial irradiation, total body irradiation and, in one report, with chemotherapy alone.54-58 The reports indicate that thyroid cancer develops 12 to 13 years after treatment, the risk is highest in younger children, and the secondary thyroid cancer is associated with an excellent long-term outcome. Four patients developed papillary carcinoma of the thyroid in our cohort at a median of 9.7 years from treatment, placing this patient population at a 13-fold increased risk when compared with the general population. Radiation to the craniospinal axis was associated with an increased risk, and all 4 patients were alive at the time of this report, indicating that after cranial irradiation patients require long-term clinical monitoring of the thyroid and cervical areas for nodules.

We found that, after a relatively short latent period (0.9 years), the cumulative incidence of secondary AML/MDS rose sharply, but it appeared to reach a plateau after 5.5 years, with a median time to development of secondary AML/MDS of 3.1 years. This is consistent with data from other studies.59,60 Pui et al reported the risk of epipodophyllotoxin-related secondary AML in patients with ALL to be 3.8% at 6 years.13 They also demonstrated that the risk of epipodophyllotoxin-related AML depends largely on the schedule of drug administration. The cumulative incidence of secondary AML of 0.2% in our cohort is much lower than that reported by Pui et al, in part because epipodophyllotoxins were not used in any of the therapeutic protocols used in this cohort of patients.

Hodgkin disease15,61,62 and NHL11 15 as second neoplasms have been reported in previous studies. In our cohort, the risks of developing secondary Hodgkin disease and NHL were increased 3-fold and 8-fold, respectively, compared with the general population.

Comparison of the 2 treatment eras (1983-1989 vs 1989-1995) showed that a significantly larger proportion treated in the recent era received anthracyclines and cyclophosphamide. Patients treated in the early era were more likely to have received prophylactic cranial radiation compared with those treated in the recent era. Despite these differences in exposure, there is no statistically significant difference in the incidence of second malignancies in the 2 eras within the first 5 years of follow-up. The median length of follow-up was shorter for the recent era (4.6 years vs 10.3 years for the early era) and so may not allow a meaningful comparison of late-occurring malignancies such as brain tumors and other solid cancers typically associated with radiation. However, secondary AML typically has a short latency period, with most events within the first 4 to 7 years and relatively few events described after the first decade. Therefore, in our cohort, we can say that incidence of secondary AML appears comparable in the 2 treatment eras and has remained constant over the last 15 years.

This study has many strengths. First, the large number of patients treated between 1983 and 1995 allowed us to describe the incidence of second malignant neoplasms among patients treated on contemporary therapeutic protocols. Second, treatment of patients according to CCG therapeutic protocols ensured uniform access to standard therapy, giving us the opportunity to explore risk factors associated with second malignant neoplasms identified in this cohort.

Several limitations to our report also need to be discussed. Although all the patients in our cohort were treated according to therapeutic protocols, we do not have detailed information regarding actual doses of therapeutic exposures given to patients for relapses, which potentially could have influenced the development of second malignancies. Therefore, we included history of relapse as a variable in the multivariate analysis to serve as a surrogate marker for further therapy received. Relapse of primary disease was associated with increased risk of all second neoplasms, AML/MDS, and all solid tumors.

Another limitation of this study was the relatively short overall follow-up period for this cohort, the median length of follow-up of this cohort being 5.5 years. However, the cohort has contributed 54 883 person-years of observation. In addition, 3713 patients from the early era were observed for a median of 10.3 years, contributing 31 558 person-years of observation. The cumulative incidence of second neoplasms developing among patients treated in the early era approached 0.9% at 10 years from diagnosis and represents a fairly accurate estimate of the incidence of second neoplasms among patients treated on contemporary risk-based therapy. However, although most previous studies reported a median follow-up ranging from 4.6 years11 to 7.6 years,14 we anticipate that longer follow-up will likely result in identification of more second neoplasms, especially those associated with radiation therapy, such as brain tumors. Furthermore, longer follow-up of the recent era will give us a more accurate estimate of the impact of the conservative use of prophylactic radiation on the incidence of radiation-associated second malignancies.

The current therapeutic approach to childhood ALL is risk stratification, with aggressive chemotherapy and radiation therapy reserved for patients considered at high risk for relapses and adverse outcomes. Follow-up of this large cohort shows that, with contemporary risk-based therapies, the incidence rate of second neoplasms remains low throughout the first decade after diagnosis of childhood ALL, although it is higher than expected in the general population.

Supported in part by 5 U10 CA13539-26S2.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

1
Gurney
JG
Severson
RK
Davis
S
Robison
LL
Incidence of cancer in children in the United States: sex-, race-, and 1-year age-specific rates by histologic type.
Cancer.
75
1995
2186
2195
2
Reis
LAG
Eisner
MP
Kosary
CL
et al
SEER Cancer Statistics Review, 1973-1998, National Cancer Institute.
2001
NCI
Bethesda, MD
3
Brouwers
P
Poplack
O
Memory and learning sequelae in long-term survivors of acute lymphoblastic leukemia: association with attention deficits.
Pediatr Hematol Oncol.
12
1990
174
181
4
Fisher
J
Aur
R
Endocrine assessment in childhood acute lymphocytic leukemia.
Cancer.
49
1982
145
151
5
Pasqualini
T
Escobar
ME
Domene
H
Muriel
FS
Pavlovsky
S
Rivarola
MA
Evaluation of gonadal function following long-term treatment for acute lymphoblastic leukemia in girls.
J Pediatr Hematol Oncol.
9
1987
15
22
6
Blatt
J
Poplack
D
Sherins
R
Testicular function in boys following chemotherapy for acute lymphoblastic leukemia.
N Engl J Med.
304
1981
1121
1124
7
Quigley
C
Cowell
C
Jimenez
M
et al
Normal or early development of puberty despite gonadal damage in children treated for acute lymphoblastic leukemia.
N Engl J Med.
321
1989
143
151
8
Hamre
MR
Robison
LL
Nesbit
ME
et al
Effects of radiation on ovarian function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group.
J Clin Oncol.
5
1987
1759
1765
9
Lipshultz
SE
Colan
SD
Gelber
RD
Perez-Atayde
AR
Sallan
SE
Sanders
SP
Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood.
N Engl J Med.
324
1991
808
815
10
Loning
L
Zimmermann
M
Reiter
A
et al
Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial therapy.
Blood.
95
2000
2770
2775
11
Neglia
JP
Meadows
AT
Robison
LL
et al
Second neoplasms after acute lymphoblastic leukemia in childhood.
N Engl J Med.
325
1991
1330
1336
12
Mosijczuk
AD
Ruymann
FB
Second malignancy in acute lymphocytic leukemia.
Am J Dis Child.
135
1981
313
316
13
Pui
CH
Behm
FG
Raimondi
SC
et al
Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia.
N Engl J Med.
321
1989
136
142
14
Dalton
VMK
Gelber
RD
Li
F
Donnelly
MJ
Tarbell
NJ
Sallan
SE
Second malignancies in patients treated for childhood acute lymphoblastic leukemia.
J Clin Oncol.
16
1998
2848
2853
15
Zarrabi
MH
Rosner
F
Grunwald
HW
Second neoplasms in acute lymphoblastic leukemia.
Cancer.
52
1983
1712
1719
16
Walter
AW
Hancock
ML
Pui
C-H
et al
Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude Children's Research Hospital.
J Clin Oncol.
16
1998
3761
3767
17
Shapiro
S
Mealey
J
Late anaplastic gliomas in children previously treated for acute lymphoblastic leukemia.
Pediatr Neurosci.
15
1989
176
180
18
Mike
V
Meadows
AT
D'Angio
GJ
Incidence of second malignant neoplasm in children: results of an international study.
Lancet.
2
8311
1982
1326
1331
19
Hawkins
MM
Draper
GJ
Kingston
JE
Incidence of second primary tumour among childhood cancer survivors.
Br J Cancer.
56
1987
339
347
20
Rosso
P
Terracini
B
Fears
TR
et al
Second malignant tumors after elective end of therapy for a first cancer in childhood: a multicenter study in Italy.
Int J Cancer.
59
1994
451
456
21
Green
DM
Zevon
MA
Reese
PA
et al
Second malignant tumors following treatment during childhood and adolescence for cancer.
Med Pediatr Oncol.
22
1994
1
10
22
Tucker
MA
D'Angio
GJ
Boice
JD
Jr
et al
Bone sarcomas linked to radiotherapy and chemotherapy in children.
N Engl J Med.
317
1987
588
593
23
Malone
M
Lumley
H
Erdohazi
M
Astrocytoma as a second malignancy in patients with acute lymphoblastic leukemia.
Cancer.
57
1986
1979
1985
24
Fontana
M
Stanton
C
Pompili
A
et al
Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia.
Cancer.
60
1987
1510
1518
25
Rimm
IJ
Li
FC
Tarbell
NJ
Winston
KR
Sallan
SE
Brain tumors after cranial irradiation for childhood acute lymphoblastic leukemia. A 13-year experience from the Dana-Farber Cancer Institute and the Children's Hospital.
Cancer.
59
1987
1506
1508
26
Judge
MR
Eden
OB
O'Neill
P
Cerebral glioma after cranial prophylaxis for acute lymphoblastic leukemia.
Br Med J.
289
1984
1038
1039
27
Vowels
MR
Tobias
V
Mameghan
H
Second intracranial neoplasms following treatment of childhood acute lymphoblastic leukemia.
J Paediatr Child Health.
27
1991
43
46
28
Relling
MV
Rubnitz
JE
Rivera
GK
et al
High incidence of secondary brain tumors after radiotherapy and antimetabolites.
Lancet.
354
1999
34
39
29
Jenkinson
H
Hawkins
M
Secondary brain tumors in children with ALL.
Lancet.
354
1999
1126
30
Stanulla
M
Loning
L
Welte
K
Schrappe
M
Secondary brain tumors in children with ALL.
Lancet.
354
1999
1126
1127
31
Stein
ME
Drumea
K
Guilbord
JN
Ben-Itzhak
O
Kuten
A
Case report: late aggressive meningioma following prophylactic cranial irradiation for acute lymphoblastic leukemia.
Br J Radiol.
68
1995
1123
1125
32
Hutchinson
RJ
Neerhout
RC
Bertolone
S
Should therapy be intensified for patients with good risk ALL? [abstract].
Blood.
88
1996
668a
33
Lange
B
Sather
H
Weetman
R
et al
Double delayed intensification improves outcome in moderate risk pediatric acute lymphoblastic leukemia (ALL): a Children's Cancer Group study, CCG-1891 [abstract].
Blood.
90
1997
559a
34
Uckun
FM
Reaman
G
Steinherez
PG
et al
Improved outcome for children with T-lineage acute lymphoblastic leukemia after contemporary chemotherapy: a Children's Cancer Group study.
Leuk Lymphoma.
24
1996
57
70
35
Uckun
FM
Gaynon
PS
Sensel
MG
et al
Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study.
J Clin Oncol.
15
1997
2214
2221
36
Uckun
FM
Sensel
MG
Sun
L
et al
Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.
Blood.
91
1998
735
746
37
Bostrom
B
Gaynon
P
Sather
H
Dexamethasone (DEX) decreases central nervous system (CNS) relapse and improves event-free survival (EFS) in lower risk acute lymphoblastic leukemia (ALL) [abstract].
Proc Am Soc Clin Oncol.
17
1998
527a
38
Reaman
GH
Sposto
R
Sensel
MG
et al
Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.
J Clin Oncol.
17
1999
445
455
39
Nachman
JB
Sather
HN
Sensel
MG
et al
Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.
N Engl J Med.
338
1998
1663
1671
40
Nachman
J
Sather
HN
Cherlow
JM
et al
Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.
J Clin Oncol.
16
1998
920
930
41
Steinherz
PG
Gaynon
PS
Breneman
JC
et al
Treatment of patients with acute lymphoblastic leukemia with bulky extramedullary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children's Cancer Group.
Cancer.
82
1998
600
612
42
Nachman
J
Sather
HN
Gaynon
PS
Lukens
JN
Wolff
L
Trigg
ME
Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
J Clin Oncol.
15
1997
2222
2230
43
Kelsey
JL
Thomson
WD
Evans
AS
Retrospective Cohort Studies
Methods in Observational Epidemiology.
1986
128
147
Oxford University Press
New York, NY
44
Nygaard
R
Garwicz
S
Haldorsen
T
et al
Second malignant neoplasms in patients treated for childhood leukemia.
Acta Paediatr Scand.
80
1991
1220
1228
45
Pratt
CB
George
SL
Hannock
ML
Hustu
HO
Kun
LE
Ochs
JS
Second malignant neoplasms in survivors of childhood acute lymphocytic leukemia [abstract].
Pediatr Res.
23(suppl)
1988
345a
46
Neglia
JP
Friedman
DL
Yasui
Y
et al
Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study.
J Natl Cancer Inst.
93
2001
618
629
47
Sullivan
MP
Chen
T
Dyment
PG
Hvizdala
E
Steuber
CP
Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute leukemia: a Pediatric Oncology Group study.
Blood.
60
1982
948
958
48
Littman
P
Coccia
P
Bleyer
WA
et al
Central nervous system (CNS) prophylaxis in children with low risk acute lymphoblastic leukemia (ALL).
Int J Radiat Oncol Biol Phys.
13
1987
1443
1449
49
Brustle
O
Ohgaki
H
Schmitt
HP
Walter
GF
Ostertag
H
Kleihues
P
Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children: association with an activated K-ras gene.
Cancer.
69
1992
2385
2392
50
Malkin
D
Li
FP
Strong
LC
et al
Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms.
Science.
250
1990
1233
1238
51
Farwell
J
Flannery
J
Cancer in relatives of children with central nervous system neoplasms.
N Engl J Med.
311
1984
749
753
52
Hisada
M
Garber
JE
Fung
CY
Fraumeni
JF
Jr
Li
FP
Multiple primary cancers in families with Li-Fraumeni syndrome.
J Natl Cancer Inst.
90
1998
606
611
53
Prasannan
L
Pu
A
Hoff
P
Weatherly
R
Castle
V
Parotid carcinoma as a second malignancy after treatment of childhood acute lymphoblastic leukemia.
J Pediatr Hematol Oncol.
21
1999
535
538
54
Perel
Y
Leverger
G
Carrere
A
et al
Second thyroid neoplasms after prophylactic cranial irradiation for acute lymphoblastic leukemia.
Am J Hematol.
59
1998
91
94
55
Kuefer
MU
Moinuddin
M
Heideman
RL
et al
Papillary thyroid carcinoma: demographics, treatment, and outcome in eleven pediatric patients treated at a single institution.
Med Pediatr Oncol.
28
1997
433
440
56
Uderzo
C
van Lint
MT
Rovelli
A
et al
Papillary thyroid carcinoma after total body irradiation.
Arch Dis Child.
71
1994
256
258
57
Hosoya
R
Eiraku
K
Saiki
S
Nishimura
K
Thyroid carcinoma and acute lymphoblastic leukemia in childhood.
Cancer.
15
1983
1931
1933
58
Tang
TT
Holcenberg
JS
Duck
SC
Hodach
AE
Oechler
HW
Camitta
BM
Thyroid carcinoma following treatment for acute lymphoblastic leukemia.
Cancer.
46
1981
1572
1576
59
Bhatia
S
Robison
LL
Oberlin
O
et al
Breast cancer and other second neoplasms after childhood Hodgkin's disease.
N Engl J Med.
334
1996
745
751
60
Blayney
DW
Longo
DL
Young
RC
et al
Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.
N Engl J Med.
316
1987
710
714
61
Peeters
MA
Smith
C
Saunders
EF
Secondary Hodgkin's disease in childhood acute lymphoblastic leukemia.
Med Pediatr Oncol.
14
1986
230
233
62
Labotka
RJ
Sotelo-Avila
C
Hruby
MA
Hodgkin's disease in a child with acute lymphoblastic leukemia.
Cancer.
52
1983
846
850

Author notes

S. Bhatia, Children's Oncology Group, PO Box 60012, Arcadia, CA 91006-0012; e-mail: sbhatia@coh.org; cc:smason@childrensoncologygroup.org.

Sign in via your Institution